Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cell

1. A lipid particle comprising:

(i) at least one cationic lipid,

(ii) at least one water-soluble therapeutically effective compound, wherein the therapeutically effective compound is a bisphosphonate, and

(iii) RNA encoding at least one antigen,

wherein the particle comprises a lamellar internal organization comprising 2 to 40 lamellae per row.

2. The particle of claim 1 , wherein the lipid forms a structure receiving the at least one water soluble therapeutically effective compound and the RNA.

3. The particle of claim 1 , wherein the lamellar internal organization comprises 2 to 20, 2 to 10, or 3 to 8 lamellae per row.

4. The particle of claim 1 , wherein the RNA is pharmaceutically active or encodes at least one pharmaceutically active peptide or protein.

5. The particle of claim 1 , wherein the antigen is a disease-associated antigen or elicits an immune response against a disease-associated antigen or cells expressing a disease-associated antigen.

6. The particle of claim 1 , wherein the bisphosphonate has a molecular mass lower than 1000 Da.

7. The particle of claim 1 , wherein the bisphosphonate is selected from the group consisting of zoledronic acid, clodronic acid, ibandronic acid, pamidronic acid, risedronic acid, minodronic acid, olpadronic acid, alendronic acid, incadronic acid, and salts thereof.

8. The particle of claim 1 , which comprises at least one helper lipid.

9. The particle of claim 8 , wherein the helper lipid is a neutral lipid or negatively charged lipid.

10. The particle of claim 1 , wherein the at least one cationic lipid comprises 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMEPC), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) and/or 1,2-dioleoyl-3-trimethylammonium propane (DOTAP).

11. The particle of claim 8 , wherein the at least one helper lipid comprises 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE), cholesterol (Chol), 1-palmitoyl-2-oleoyl-sn-glycero-3phosphocholin (POPC) and/or 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).

12. The particle of claim 1 , wherein the particle has an average diameter in the range of from about 50 nm to about 1000 nm.

13. The particle of claim 12 , wherein the particle has an average diameter

(i) in the range of from about 50 nm to about 400 nm, from about 50 nm to about 200 nm, or

(ii) in the range of from about 200 nm to about 1000 nm, from about 200 nm to about 800 nm, more from about 300 nm to about 600 nm.

14. The particle of claim 1 , which is obtainable by addition of the RNA to a colloidal lipid dispersion comprising the at least one cationic lipid and the at least one water-soluble therapeutically effective compound.

15. The particle of claim 14 , wherein the colloidal lipid dispersion comprising the at least one cationic lipid and the at least one water-soluble therapeutically effective compound is obtainable by injection of an ethanol solution of the lipids into an aqueous phase comprising the at least one water-soluble therapeutically effective compound.

16. A pharmaceutical composition comprising a lipid particle and a pharmaceutically acceptable carrier, wherein the lipid particle comprises:

(i) at least one cationic lipid,

(ii) at least one water-soluble therapeutically effective compound, wherein the therapeutically effective compound is a bisphosphonate, and

(iii) RNA encoding at least one antigen, and

wherein the particle comprises a lamellar internal organization comprising 2 to 40 lamellae per row.

17. The particle of claim 1 , wherein the bisphosphonate is a nitrogen-containing bisphosphonate (aminobisphosphonate).